Literature DB >> 20136645

In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida experience.

Johnny Ray Bernard1, Laura A Vallow, Elizabeth R DePeri, Rebecca B McNeil, Deborah G Feigel, Surabhi Amar, Steven J Buskirk, Edith A Perez.   

Abstract

The role of magnetic resonance imaging (MRI) in patients with newly diagnosed breast cancer is somewhat controversial. The purpose of this study was to evaluate the prevalence of synchronous, occult contralateral breast cancer detected by MRI but not by mammography or clinical breast examination in women with newly diagnosed breast cancer, including those aged 70 years or older at our institution. MRI results for women with newly diagnosed breast cancer who underwent bilateral breast MRI after negative mammography and clinical examination between February 2003 and November 2007 at Mayo Clinic in Florida were reviewed. The prevalence of pathologically confirmed contralateral carcinoma diagnosed solely by MRI was determined and analyzed in the context of age, family history, menopausal status, breast density, and primary-tumor characteristics. Logistic regression was used to explore the association between contralateral carcinoma and potential patient risk factors. A total of 425 women were evaluated, of whom 129 (30%) were aged 70 years or older. A contralateral biopsy was recommended and performed solely on the basis of MRI in 72 of the 425 women (17%). Sixteen of these 72 women (22%) had pathologically confirmed carcinoma, including seven in the older subgroup. The prevalence of clinically and mammographically occult contralateral carcinoma detected by MRI was 3.8% (16/425) overall and 5.4% (7/129) in the group of older women. When potential risk factors for contralateral breast cancer were evaluated, postmenopausal status was the only significant predictor of contralateral cancer detected by MRI (p = 0.016). We concluded that contralateral breast screening with MRI should be considered in postmenopausal women with newly diagnosed breast cancer, even those aged 70 years or older at diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20136645     DOI: 10.1111/j.1524-4741.2009.00890.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

Review 1.  Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis.

Authors:  María Nieves Plana; Carmen Carreira; Alfonso Muriel; Miguel Chiva; Víctor Abraira; Jose Ignacio Emparanza; Xavier Bonfill; Javier Zamora
Journal:  Eur Radiol       Date:  2011-08-17       Impact factor: 5.315

2.  Outcomes of surveillance for contralateral breast cancer in patients less than age 60 at the time of initial diagnosis.

Authors:  C Weinstock; R Bigenwald; T Hochman; P Sun; S A Narod; E Warner
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

3.  Preoperative Breast Magnetic Resonance Imaging Use by Breast Density and Family History of Breast Cancer.

Authors:  Louise M Henderson; Rebecca A Hubbard; Weiwei Zhu; Julie Weiss; Karen J Wernli; Martha E Goodrich; Karla Kerlikowske; Wendy DeMartini; Elissa M Ozanne; Tracy Onega
Journal:  J Womens Health (Larchmt)       Date:  2018-01-15       Impact factor: 2.681

Review 4.  Impact of preoperative breast MRI on surgical decision making and clinical outcomes: a systematic review.

Authors:  Armen Parsyan; Awadh Alqahtani; Benoit Mesurolle; Sarkis Meterissian
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

5.  Evaluation of expert criteria for preoperative magnetic resonance imaging of newly diagnosed breast cancer.

Authors:  Carolyn E Behrendt; Lusine Tumyan; Laura Gonser; Sara L Shaw; Lalit Vora; I Benjamin Paz; Joshua D I Ellenhorn; John H Yim
Journal:  Breast       Date:  2014-02-14       Impact factor: 4.380

6.  Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.

Authors:  Richard J Santen; Wei Yue; Daniel F Heitjan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-14       Impact factor: 4.254

Review 7.  Rethinking prostate cancer screening: could MRI be an alternative screening test?

Authors:  David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2020-07-21       Impact factor: 14.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.